LAS VEGAS, Aug. 4, 2020 /PRNewswire/ -- JanOne Inc.
(Nasdaq: JAN), a company focused on bringing treatments to market
for conditions that cause severe pain and drugs with non-addictive,
pain-relieving properties, announces a internal name change
for its current drug candidate from TV1001SR to JAN101, soon to
enter Phase 2b clinical trials as a
potential treatment Peripheral Artery Disease (PAD). The name
change will be effective immediately and will be used in all its
current and future clinical trials, Indications for a New Drug,
clinical and research studies planned to be conducted in the
future.
According to JanOne's chief executive officer, Tony Isaac, "This internal name change better
reflects the new naming convention for all clinical candidates
offered in the JanOne pipeline moving forward."
About JanOne
JanOne (NASDAQ: JAN) is focused on
bringing medications to market to treat diseases that cause severe
pain. By alleviating pain at the source, JanOne aims to reduce the
need for opioid prescriptions to treat disease associated pain that
can lead to opioid abuse. The company is also exploring solutions
for non-addictive pain medications. Its lead candidate JAN101 is
for treating peripheral artery disease (PAD), a condition that
affects over 8.5 million Americans. JAN101 demonstrated positive
results in a Phase 2a clinical trial and Phase 2b trials are expected to begin in early 2021.
JanOne is dedicated to funding resources toward innovation,
technology, and education for PAD, associated vascular conditions
and neuropathic pain. JanOne continues to operate its legacy
businesses under their current brand names, ARCA Recycling and
GeoTraq, both of which are undergoing review to determine
appropriate strategic alternatives. For more information,
visit janone.com
Media contact:
ir@Janone.com
1 (800) 400-2247
View original content to download
multimedia:http://www.prnewswire.com/news-releases/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101-301105590.html
SOURCE JanOne